Bicycle Therapeutics (BCYC) Projected to Release Quarterly Earnings on Friday

Bicycle Therapeutics (NASDAQ:BCYC) will likely be posting its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect the company to post earnings of ($0.5756) per share and revenue of $4.2210 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 7:00 AM ET.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.14). Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. The company had revenue of $0.63 million for the quarter, compared to the consensus estimate of $4.22 million. On average, analysts expect Bicycle Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Bicycle Therapeutics Stock Up 0.5%

Shares of NASDAQ:BCYC opened at $3.96 on Wednesday. The business’s 50 day moving average is $4.16 and its 200 day moving average is $4.88. The stock has a market cap of $276.45 million, a P/E ratio of -1.45 and a beta of 1.55. Bicycle Therapeutics has a 52-week low of $3.74 and a 52-week high of $9.16.

Insider Activity at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 5,905 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total transaction of $25,214.35. Following the completion of the sale, the chief executive officer directly owned 605,408 shares in the company, valued at $2,585,092.16. This represents a 0.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 9,977 shares of company stock valued at $42,702. Insiders own 22.00% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Hedge funds have recently modified their holdings of the company. Armistice Capital LLC grew its position in shares of Bicycle Therapeutics by 6.4% in the 3rd quarter. Armistice Capital LLC now owns 2,978,000 shares of the company’s stock worth $23,050,000 after buying an additional 178,000 shares during the last quarter. GSK plc purchased a new position in Bicycle Therapeutics in the fourth quarter worth $10,829,000. Bank of America Corp DE increased its position in shares of Bicycle Therapeutics by 47.4% during the second quarter. Bank of America Corp DE now owns 830,634 shares of the company’s stock worth $5,773,000 after purchasing an additional 267,075 shares in the last quarter. Schroder Investment Management Group purchased a new stake in shares of Bicycle Therapeutics during the 4th quarter valued at $3,976,000. Finally, Renaissance Technologies LLC boosted its position in shares of Bicycle Therapeutics by 9.2% in the 4th quarter. Renaissance Technologies LLC now owns 566,600 shares of the company’s stock worth $4,012,000 after purchasing an additional 47,900 shares in the last quarter. 86.15% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BCYC shares. Wall Street Zen raised Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, April 30th. Needham & Company LLC dropped their target price on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Morgan Stanley cut their target price on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Wednesday, July 8th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $13.86.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.